Overview

Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain

Status:
Terminated
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to investigate if AZD1386 is efficacious as an analgesic in patients with peripheral neuropathic pain. This will be done by comparing the effect of AZD1386 to placebo ("inactive substance") on pain.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca